Preparing an Investigational New Drug (IND) submission is one of the most important milestones in drug development.
Yet for many organizations, the greatest challenge is not generating data.
The challenge is understanding whether the available evidence sufficiently supports regulatory expectations.
Scientific data may exist.
Documentation may exist.
Consultant recommendations may exist.
However, teams often struggle to answer a critical question:
Are we truly ready for IND submission?
IND readiness is the process of connecting regulatory expectations, available evidence, identified gaps, and readiness decisions into a clear operational framework.
This guide explains what IND readiness means, why it matters, common challenges organizations face, and practical approaches for improving readiness throughout development.
Introduction
"What Is IND Readiness?"
IND readiness refers to an organization's ability to demonstrate that sufficient evidence, documentation, and supporting information exist to advance toward an Investigational New Drug submission.
Readiness is not a single document.
It is a continuously evolving assessment of whether regulatory expectations are being adequately addressed.
Successful readiness programs help organizations answer:
- What evidence is required?
- What evidence currently exists?
- Which expectations remain unsupported?
- What gaps remain unresolved?
- How prepared are we for submission?
Why IND Readiness Matters
Many development programs generate substantial amounts of information.
However, data alone does not guarantee readiness.
Organizations frequently encounter challenges such as:
- Missing supporting documentation
- Incomplete evidence packages
- Unresolved CMC questions
- Traceability issues
- Late-stage gap discovery
These issues can delay preparation activities and increase uncertainty as submission milestones approach.
Readiness programs help identify problems earlier when corrective actions are typically less disruptive.
The IND Readiness Lifecycle
Identify Regulatory Expectations
The first step is understanding applicable expectations. These may originate from: - FDA guidance - ICH guidelines - CMC expectations - Therapeutic-area considerations - Historical regulatory feedback Organizations must determine which expectations are relevant to their specific program.
Collect Available Evidence
Evidence often exists across multiple systems and teams. Examples include: - Study reports - Analytical data - Quality documentation - Manufacturing information - Regulatory documentation The objective is to establish visibility into available supporting materials.
Map Evidence to Expectations
Readiness improves when evidence is linked directly to relevant expectations. This helps teams understand: - Which expectations are supported - Which evidence is available - Which areas require further work Without traceability, readiness assessments become increasingly difficult.
Identify Gaps
Not every expectation will be fully supported. Gap identification helps organizations determine: - Missing evidence - Outdated documentation - Incomplete studies - Outstanding questions Gap visibility enables earlier planning and prioritization.
Assess Readiness
Organizations evaluate the overall readiness of the program based on evidence coverage, unresolved risks, and submission objectives. Readiness should be treated as an ongoing assessment rather than a one-time milestone review. ---
Common Challenges in IND Readiness
Fragmented Evidence
Evidence often resides across scientific platforms, laboratory systems, quality systems, and shared repositories. This fragmentation makes readiness assessments difficult.
Limited Traceability
Teams frequently struggle to demonstrate how evidence supports specific regulatory expectations.
Point-in-Time Assessments
Many organizations perform readiness reviews only at major milestones. Issues discovered late can be expensive to address.
Cross-Functional Coordination
Regulatory affairs, CMC, quality, manufacturing, and scientific teams often contribute to readiness activities. Maintaining alignment can be challenging.
Evolving Expectations
Regulatory expectations may evolve throughout development, requiring ongoing reassessment. ---
The Importance of Evidence Traceability
One of the most common readiness challenges is understanding how available evidence supports regulatory expectations.
Evidence traceability helps organizations answer:
- Which expectation does this evidence support?
- Which expectations lack supporting evidence?
- Which gaps represent the highest risk?
Without traceability, readiness often depends heavily on manual reviews and institutional knowledge.
CMC Readiness and IND Preparation
Chemistry, Manufacturing, and Controls (CMC) activities play a critical role in IND readiness.
Organizations must often evaluate:
- Manufacturing readiness
- Process documentation
- Analytical methods
- Quality controls
- Supporting evidence
CMC readiness should be evaluated continuously rather than immediately before submission preparation begins.
Indicators of a Mature IND Readiness Program
Organizations with mature readiness capabilities often demonstrate:
- Clear expectation management
- Structured evidence mapping
- Continuous gap tracking
- Cross-functional collaboration
- Readiness visibility across teams
- Ongoing assessment processes
These capabilities help reduce uncertainty and improve decision-making throughout development.
Related Resources
- Why IND Readiness Is Still Broken: The Missing Layer Between Scientific Evidence and Regulatory Submission
- Common Reasons IND Applications Are Delayed
- Evidence Traceability for IND Readiness
- CMC Documentation Readiness Framework
About BeaconOS
BeaconOS helps biopharma organizations connect regulatory expectations, available evidence, identified gaps, and readiness decisions.
Positioned between scientific systems and submission platforms, BeaconOS provides continuous visibility into IND readiness by helping teams map expectations to evidence, identify readiness gaps, and support more informed regulatory decision-making throughout development.